Teva Pharmaceutical Industries Limited recently presented the findings from its Phase Ib clinical trial of the Anti-IL-15 antibody, which targets vitiligo. The results indicate significant efficacy over a 24-week period.
The study's outcomes have prompted Teva to plan the advancement of the trial into Phase 2b, where further evaluation of the antibody's effectiveness will take place.
This development is a crucial step for Teva as it seeks to provide new treatment options for patients suffering from vitiligo, a condition characterized by skin depigmentation.